Filing Details

Accession Number:
0000950170-24-005380
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-01-18 16:10:54
Reporting Period:
2024-01-16
Accepted Time:
2024-01-18 16:10:54
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1743881 Bridgebio Pharma Inc. BBIO Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1855608 Hannah Valantine C/O Bridgebio Pharma, Inc.
3160 Porter Dr., Suite 250
Palo Alto CA 94304
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-01-16 2,915 $8.45 4,679 No 4 M Direct
Common Stock Disposition 2024-01-16 2,915 $37.97 1,764 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2024-01-16 2,915 $0.00 2,915 $8.45
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
96,176 2032-06-22 No 4 M Direct
Footnotes
  1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 16, 2023.
  2. 1/3rd of the shares underlying the option vested on June 22, 2023; thereafter, 1/3rd of the underlying shares vest on an annual basis, so that all of the underlying shares will be vested on June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company.